Biogen, Eisai’s lecanemab gets the Alzheimer’s nod, but how successful it will be uncertain

elderly patient

agrobacter/iStock via Getty Images

The US FDA on Friday issued accelerated approval of Biogen (NASDAQ:BIIB) and Eisai’s (OTCPK:ESALY) Leqembi (lecanemab), is only the second biologic drug ever approved for Alzheimer’s disease.

The therapy is expected to be available worldwide

Source by [author_name]


News7h: Update the world's latest breaking news online of the day, breaking news, politics, society today, international mainstream news .Updated news 24/7: Entertainment, the World everyday world. Hot news, images, video clips that are updated quickly and reliably

Related Articles

Back to top button